The market regulatory authorities in Shiquan County, Ankang City, Shaanxi Province, have systematically planned and implemented precise measures in 2025, focusing on high-quality development goals. They have achieved breakthroughs in various segments of the Qinba pharmaceutical industry, including top-level design, seed source assurance, standard establishment, platform construction, and processing extension, laying a solid foundation for building a regionally distinctive and advantageous industrial cluster.
The Shiquan County Party Committee and County Government convened an industrial development symposium to decompose key tasks, assign responsibilities, and clarify the "3+2" industrial development path. This strategy is centered on three dominant varieties—perilla, polygonatum sibiricum, and epimedium—and two processing categories—kudzu root and mugwort.
Concurrently, the county reconstituted the Traditional Chinese Medicine Association to further leverage the industry association's role as a bridge in standard formulation, industry self-regulation, information services, and connecting production with sales.
To address the bottleneck in the supply of high-quality seedlings, Shiquan County has made sustained efforts in the seedling propagation sector. A high-content epimedium seedling breeding base, constructed with investment from Shaanxi Jialang Biotechnology Co., has been completed and put into operation. It boasts an annual capacity to supply 50 million high-quality seedlings, providing crucial support for the scaled and standardized expansion of this core variety.
Furthermore, the Bletilla striata seedling base built by Qiancaoyuan Agriculture has achieved an annual production capacity of 30 million seedlings. Its products have successfully entered markets outside the province, signaling a significant enhancement in the county's medicinal herb seedling cultivation technology and market competitiveness.
In promoting industrial standardization, Shiquan County has taken substantial strides. In 2025, its perilla planting base successfully obtained the national GAP (Good Agricultural Practice) certification, marking a breakthrough for the county in the certified, standardized cultivation of Chinese medicinal herbs.
Building on this foundation, Shiquan County plans to initiate GAP certification for varieties such as polygonatum sibiricum and epimedium in 2026, driving the entire industry towards a transformation characterized by high standards and superior quality.
The year 2025 has emerged as a pivotal year for major project advancement in Shiquan's Qinba pharmaceutical industry. The Qinling Chinese Medicinal Materials Trading and Distribution Center, envisioned as a future regional industrial hub, has been finalized and commenced construction. It is expected to significantly enhance capabilities in herb distribution, information exchange, and logistics support.
Simultaneously, the Shiquan Polygonatum Sibiricum Deep Processing Project, which signifies a deepening extension of the industrial chain into sophisticated processing, has broken ground. The concurrent progress of these two major projects establishes a dual-drive framework of "front-end trading platform + back-end value-added processing," making the path for industrial agglomeration effects and added-value enhancement increasingly clear.
In 2026, the development of Shiquan's Qinba pharmaceutical industry will focus on sustained efforts across five key areas: scaled and standardized planting, improvement of the processing system, enhancement of brand value, strengthening of factor guarantees, and deepening industrial integration. The county is committed to fully advancing the quality upgrade of the Qinba pharmaceutical industry chain.
Comments